STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANGO
  4. [Form 4] ANGIODYNAMICS INC Insider Trading Activity

AngioDynamics (ANGO) director receives 11,887 RSUs that vest immediately

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Burgess Lorinda reported acquisition or exercise transactions in this Form 4 filing.

AngioDynamics director Lorinda Burgess received an equity award of 11,887 restricted stock units as regular annual compensation for board service on July 15, 2026. These RSUs immediately vested at grant, increasing her directly held common stock to 67,144 shares. The award was a no-cost stock grant and was not made under a Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider Burgess Lorinda
Role Director
Type Security Shares Price Value
Grant/Award Common Stock F1 11,887 $0.00 $0.00
Holdings After Transaction: Common Stock — 67,144 shares (Direct)
Footnotes (1)
  1. F1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.
Shares awarded 11,887 shares Restricted stock units granted as regular annual director compensation
Shares held after transaction 67,144 shares Common stock directly owned by Lorinda Burgess following the award
Award date July 15, 2026 Grant date of restricted stock units to Lorinda Burgess
Award price per share $0.0000 per share No-cost equity grant for board service as a director
restricted stock units financial
"represents 11,887 restricted stock units granted as regular annual compensation"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vested financial
"The restricted stock units immediately vested at the time of grant"
annual compensation financial
"granted as regular annual compensation for service as a director"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did AngioDynamics (ANGO) director Lorinda Burgess report?
Lorinda Burgess reported an equity award of 11,887 restricted stock units as regular annual compensation for serving as a director. The units immediately vested, resulting in direct ownership of 67,144 shares of AngioDynamics common stock after the grant.

How many AngioDynamics (ANGO) shares does Lorinda Burgess hold after this award?
After the award, Lorinda Burgess directly holds 67,144 shares of AngioDynamics common stock. This reflects the immediate vesting of 11,887 restricted stock units granted as part of her regular annual compensation for board service.

Was the AngioDynamics (ANGO) equity award to Lorinda Burgess a cash purchase?
No. The transaction was a no-cost equity grant of 11,887 restricted stock units, reported with a price of $0.0000 per share. It represents regular annual director compensation rather than a cash-funded open-market stock purchase.

Did Lorinda Burgess’s AngioDynamics (ANGO) award involve a Rule 10b5-1 trading plan?
The transaction was not made under a Rule 10b5-1 trading plan, as the relevant checkbox was left unchecked. It is characterized as a grant or award of restricted stock units for service as a director.

When was the AngioDynamics (ANGO) restricted stock unit grant to Lorinda Burgess made and when did it vest?
The grant of 11,887 restricted stock units to Lorinda Burgess was made on July 15, 2026. According to the disclosure, the restricted stock units immediately vested at the time of grant, converting into directly held common shares.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Burgess Lorinda
(Last)(First)(Middle)
14 PLAZA DRIVE
(Street)
LATHAM NEW YORK 12110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/15/2026A11,887(1)A$067,144D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.
/s/ Lawrence T. Weiss, Attorney in Fact07/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR